Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.46 |
| ▸ | RBP4 | P02753 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | YAP1 | P46937 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19409668 | 0.90 | GPR119 (0.48) | SCN9AGPR119RBP4KDM4EPKM | |
| SCHEMBL19409514 | 0.86 | GPR119 (0.48) | SCN9AGPR119RBP4KDM4EPKM | |
| SCHEMBL15537604 | 0.83 | GPR119 (0.50) | SCN9AGPR119KDM4EPKMALOX5AP | |
| SCHEMBL13419698 | 0.83 | GPR119 (0.50) | SCN9AGPR119KDM4EPKMALOX5AP | |
| SCHEMBL25379718 | 0.82 | GPR119 (0.53) | GPR119KDM4E | |
| SCHEMBL31330761 | 0.81 | RBP4 (0.58) | SCN9AGPR119RBP4ALOX5APFEN1 | |
| SCHEMBL16777273 | 0.80 | GPR119 (0.51) | SCN9AGPR119ALOX5APFEN1 | |
| SCHEMBL22265766 | 0.80 | KDM4E (0.54) | SCN9AGPR119KDM4EPKMALOX5AP | |
| SCHEMBL5213121 | 0.79 | TLR7 (0.51) | SCN9AGPR119KDM4EPKM | |
| SCHEMBL13419611 | 0.79 | ALDH1A1 (0.50) | SCN9AGPR119ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436444-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-13 | — | — | EP | disclosed |
| US-10323026-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-18 | — | — | US | disclosed |
| EP-3436444-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
| WO-2017171100-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | WO | disclosed |
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | SCN9A 499/4885GPR119 2126/4885RBP4 4767/4885 |
| US-10323026-B2 | Heterocyclic compound | MAG, HTT, ACHE | SCN9A 499/4885GPR119 2126/4885RBP4 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.